Crispr Therapeutics AG (NASDAQ:CRSP) Director Bradley J. Phd Bolzon sold 60,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $92.51, for a total transaction of $5,550,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Crispr Therapeutics stock opened at $85.69 on Friday. Crispr Therapeutics AG has a twelve month low of $32.30 and a twelve month high of $105.12. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 204.20 and a beta of 2.29. The company's 50 day moving average is $90.73 and its 200 day moving average is $65.51.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, July 27th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.35). Crispr Therapeutics had a net margin of 6.77% and a return on equity of 2.35%. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $19.77 million. During the same period in the previous year, the company earned ($1.01) earnings per share. Crispr Therapeutics's quarterly revenue was down 86.2% compared to the same quarter last year. As a group, equities research analysts predict that Crispr Therapeutics AG will post -4.74 earnings per share for the current fiscal year.
Several research firms recently weighed in on CRSP. Chardan Capital upped their price target on Crispr Therapeutics from $72.50 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, July 28th. William Blair reissued a "buy" rating on shares of Crispr Therapeutics in a research note on Tuesday, July 28th. Citigroup reaffirmed a "sell" rating on shares of Crispr Therapeutics in a research report on Wednesday, August 5th. Piper Sandler reissued an "overweight" rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Friday, June 19th. Finally, SunTrust Banks began coverage on shares of Crispr Therapeutics in a report on Tuesday, July 14th. They issued a "buy" rating and a $140.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company. Crispr Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $90.93.
A number of large investors have recently made changes to their positions in CRSP. Pacitti Group Inc. purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $32,000. WASHINGTON TRUST Co increased its holdings in Crispr Therapeutics by 81.9% during the second quarter. WASHINGTON TRUST Co now owns 473 shares of the company's stock valued at $35,000 after buying an additional 213 shares during the last quarter. NEXT Financial Group Inc raised its position in Crispr Therapeutics by 606.4% in the first quarter. NEXT Financial Group Inc now owns 883 shares of the company's stock worth $37,000 after acquiring an additional 758 shares during the period. Sandy Spring Bank purchased a new position in shares of Crispr Therapeutics during the 1st quarter worth $40,000. Finally, Liberty One Investment Management LLC purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $45,000. 55.29% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]